...
首页> 外文期刊>Gut Pathogens >A rhodanine agent active against non-replicating intracellular Mycobacterium avium subspecies paratuberculosis
【24h】

A rhodanine agent active against non-replicating intracellular Mycobacterium avium subspecies paratuberculosis

机译:罗丹宁剂对非复制性细胞内鸟分枝杆菌亚种副结核病有活性

获取原文
           

摘要

Background Antibiotic therapy targeting chronic mycobacterial disease is often ineffective due to problems with the emergence of drug resistance and non-replicating persistent intracellular antibiotic resistant phenotypes. Strategies which include agents able to enhance host cell killing mechanisms could represent an alternative to conventional methods with the potential for host clearance if active against dormant phenotypes. Investigations of agents with potential activity against non-replicating mycobacteria however are restricted due to a need for assays that can assess bacterial viability without having to culture. Results This study describes the development and use of a pre16S ribosomal gene RNA/DNA ratio viability assay which is independent of the need for culture, supported by a novel thin layer accelerated mycobacterial colony forming method for determining viability and culturability of MAP in intracellular environments. We describe the use of these tools to demonstrate intracellular killing activity of a novel rhodanine agent (D157070) against the intracellular pathogen Mycobacterium avium subspecies paratuberculosis (MAP) and show that the culturability of MAP decreases relative to its viability on intracellular entry suggesting the induction of a non-culturable phenotype. We further demonstrate that D157070, although having no direct activity against the culturability of extracellular MAP, can bind to cultured MAP cells and has significant influence on the MAP transcriptome, particularly with respect of δL associated genes. D157070 is shown to be taken up by bovine and human cells and able to enhance host cell killing, as measured by significant decreases in both culturability and viability of intracellular MAP. Conclusions This work suggests that pre16srRNA gene ratios represent a viable method for studying MAP viability. In addition, the rhodanine agent D157070 tested is non-toxic and enhances cell killing activity against both growing and latent MAP phenotypes.
机译:背景技术针对慢性分枝杆菌疾病的抗生素治疗通常由于无效的耐药性和非复制性持久性细胞内抗生素耐药性表型的出现而无效。包括能够增强宿主细胞杀伤机制的药物在内的策略可以代表传统方法的替代方法,如果对休眠表型具有活性,则具有清除宿主的潜力。然而,由于需要一种无需培养即可评估细菌生存力的分析方法,因此对具有抗非复制性分枝杆菌潜在活性的药物的研究受到限制。结果这项研究描述了pre16S核糖体基因RNA / DNA比活力测定法的开发和使用,该测定法与培养的需要无关,并由新颖的薄层加速分枝杆菌菌落形成方法来确定MAP在细胞内环境中的活力和可培养性。我们描述了使用这些工具来证明新型罗丹宁剂(D157070)对细胞内病原体鸟分枝杆菌亚种副结核病(MAP)的细胞内杀伤活性,并显示MAP的可培养性相对于其在细胞内进入时的生存力降低,提示诱导不可培养的表型。我们进一步证明,D157070虽然对细胞外MAP的可培养性没有直接活性,但它可以与培养的MAP细胞结合,并且对MAP转录组具有重要影响,尤其是与δL相关基因有关。 D157070被显示为被牛和人类细胞吸收,并能够增强宿主细胞的杀伤力,这通过细胞内MAP的可培养性和活力的显着降低来衡量。结论这项工作表明pre16srRNA基因比率代表了研究MAP生存力的可行方法。另外,所测试的若丹宁试剂D157070是无毒的,并且增强了针对生长中的和潜在的MAP表型的细胞杀伤活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号